Press release
Herpes Simplex Market Poised for Growth as Helicase-Primase Inhibitors Advance Toward FDA Approval
To know in detail about the herpes simplex market outlook, treatment uptake, and competitive landscape, click here: https://www.delveinsight.com/report-store/herpes-simplex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Some of the Key Facts of the Herpes Simplex Market Report
• The herpes simplex market size is expected to witness substantial growth at a significant CAGR throughout the forecast period from 2020 to 2036, driven by the chronic, recurrent nature of the disease and an advancing helicase-primase inhibitor pipeline.
• In April 2026, AiCuris announced that the US FDA granted Priority Review designation to the New Drug Application for pritelivir for the treatment of refractory HSV infection in immunocompromised patients, with a PDUFA target action date in the fourth quarter of 2026; market approval is targeted for the second half of 2026.
• In April 2026, Assembly Biosciences presented Phase Ib clinical data for its HSV helicase-primase inhibitor candidates, ABI-5366 and ABI-1179, at the 2026 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in Munich, Germany.
• Across the EU4 and the UK, gender-specific cases of herpes simplex showed a higher prevalence among females, accounting for approximately 55% of cases, compared to around 45% among males.
• In Japan, recurrent herpes simplex cases were driven predominantly by HSV-2, accounting for over ~70% of cases, with HSV-1 following at ~30%.
• In the United States, approximately 13-17% of adults have seropositivity to HSV-2, with 85-90% of these individuals remaining unaware of their infection, underscoring a substantial underdiagnosis burden.
• The HSV vaccine landscape has faced notable setbacks, with GSK discontinuing its recombinant candidate GSK3943104 after a Phase II study failed to meet its primary endpoint, and Moderna terminating its mRNA-based candidate mRNA-1608 following a Phase I/II study.
Key Herpes Simplex Companies
• Maruho, AiCuris, Assembly Biosciences, Innovative Molecules, and others.
Key Herpes Simplex Therapies
• Amenamevir (AMENALIEF), Pritelivir (AIC-316), ABI-5366, ABI-1179, Adibelivir (IM-250), and others.
• The herpes simplex market is expected to grow due to the chronic recurrent nature of the disease driving continuous suppressive therapy use, increasing awareness and screening for genital herpes, and growing demand for convenient, patient-friendly dosing regimens. The advancement of helicase-primase inhibitors targeting drug-resistant HSV is expected to further shape competitive dynamics over the forecast period.
Herpes Simplex Overview HSV is a lifelong viral infection caused by two viral types: HSV-1, which primarily causes oral herpes, and HSV-2, which is mainly associated with genital herpes. The virus spreads through direct contact with infected secretions during oral, genital, or anal contact, and establishes lifelong latency with intermittent reactivation, resulting in recurrent symptomatic outbreaks and continued transmission risk. Diagnosis is based on clinical evaluation supported by PCR testing, the most sensitive method for detecting HSV DNA from lesions, along with serologic testing to differentiate between HSV-1 and HSV-2 in asymptomatic individuals.
Get a free sample for the Herpes Simplex Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/herpes-simplex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Hrpes Simplex Market Segmentation The herpes simplex market report proffers detailed analysis for the study period 2022-2036 segmented into:
• By Region/Geography: North America (US); Europe (Germany, France, Italy, Spain, and the UK); Asia-Pacific (Japan)
• By Drugs/Therapies
• By Epidemiology Segmentation: Total Seroprevalence of HSV, Total Symptomatic Cases of HSV, Total Diagnosed Cases of HSV, Gender-specific Diagnosed Cases of HSV, Total Recurrent Cases of HSV
Download the report to understand which factors are driving herpes simplex market trends: https://www.delveinsight.com/report-store/herpes-simplex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Herpes Simplex Treatment Landscape Current treatment is primarily based on antiviral nucleoside analogs including valacyclovir and famciclovir, which remain the standard of care for episodic and suppressive therapy by inhibiting viral DNA replication, though they do not eliminate latent infection. Amenamevir (AMENALIEF), an oral helicase-primase inhibitor developed by Maruho, is approved in Japan for recurrent herpes simplex and herpes zoster, offering a novel mechanism distinct from conventional nucleoside analogs. Topical agents such as Penciclovir and Docosanol are used for herpes labialis, while resistant cases may require agents such as Foscarnet. The pipeline is advancing with helicase-primase inhibitors including Pritelivir (AiCuris), ABI-5366 and ABI-1179 (Assembly Biosciences), and Adibelivir/IM-250 (Innovative Molecules), designed to address antiviral resistance and improve long-term viral suppression.
Discover more about therapies set to grab major herpes simplex market share: https://www.delveinsight.com/report-store/herpes-simplex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Herpes Simplex Market Strengths
• A well-established base of generic nucleoside analog antivirals (valacyclovir, famciclovir, acyclovir) supports broad, low-cost, and widely accessible treatment coverage across the 7MM.
• An active late-stage pipeline, led by Pritelivir's FDA Priority Review and targeted approval in the second half of 2026, is advancing helicase-primase inhibition as a differentiated next-generation strategy.
• Multiple helicase-primase inhibitor candidates in parallel development (ABI-5366, ABI-1179, Adibelivir) broaden the competitive landscape beyond a single novel mechanism.
Herpes Simplex Market Opportunities
• Substantial underdiagnosis, with up to 85-90% of HSV-2 seropositive individuals in the US unaware of their infection, represents an opportunity for expanded screening and treatment uptake.
• Persistent unmet need for therapies effective against drug-resistant HSV in immunocompromised patients is creating opportunities for premium-priced, differentiated helicase-primase inhibitors following approval.
Scope of the Herpes Simplex Market Report
• Study Period: 2022-2036
• Historical Year: 2022-2025 | Base Year: 2026 | Forecast Period: 2026-2036
• Coverage: The US; Germany, France, Italy, Spain, and the UK; Japan
• Key Companies: Maruho, AiCuris, Assembly Biosciences, Innovative Molecules, and others
• Key Therapies: Amenamevir (AMENALIEF), Pritelivir (AIC-316), ABI-5366, ABI-1179, Adibelivir (IM-250), and others
• Market CAGR (Forecast Period): XX% (2026-2036)
• Analysis Includes: KOL views, SWOT analysis, reimbursement, conjoint analysis, unmet needs, market drivers and barriers, epidemiology patient burden
To know more about herpes simplex companies working in the market, visit: https://www.delveinsight.com/report-store/herpes-simplex-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Table of Contents
1. Herpes Simplex Market Report Introduction
2. Executive Summary for Herpes Simplex
3. SWOT Analysis of Herpes Simplex
4. Herpes Simplex Market Overview at a Glance
5. Herpes Simplex Disease Background and Overview
6. Herpes Simplex Market Segmentation and Analysis
7. Regional Analysis of the Herpes Simplex Market
8. Country-Specific Herpes Simplex Market Analysis
9. Competitive Landscape and Key Company Profiles
10. Herpes Simplex Unmet Needs
11. Herpes Simplex Emerging Therapies and Pipeline
12. Herpes Simplex Market Outlook
13. Herpes Simplex Market Access and Reimbursement
14. Herpes Simplex Market Drivers
15. Herpes Simplex Market Barriers
16. Herpes Simplex Recent Developments
17. Herpes Simplex Appendix
18. Herpes Simplex Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432, Las Vegas, Nevada 89107, United States
Website: https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma and diagnostics companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Herpes Simplex Market Poised for Growth as Helicase-Primase Inhibitors Advance Toward FDA Approval here
News-ID: 4591018 • Views: …
More Releases from Delveinsight Business Research LLP
Oral Mucositis Market Set to Grow Through 2036 as OncoZenge Advances BupiZenge T …
DelveInsight's "Oral Mucositis Treatment Market Insight, Epidemiology and Market Forecast - 2036" report delivers an in-depth analysis of oral mucositis epidemiology, market, and clinical trials, along with historical and forecasted market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
To know in detail about the oral mucositis market outlook, treatment uptake, and competitive landscape, click here: https://www.delveinsight.com/report-store/oral-mucositis-om-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Some of the Key Facts of the…
Lipodystrophy Market Set to Grow Through 2036 as Mibavademab Advances Into Phase …
DelveInsight's "Lipodystrophy - Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of lipodystrophy, historical and forecasted epidemiology, and market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
To know in detail about the lipodystrophy market outlook, treatment uptake, and competitive landscape, click here: https://www.delveinsight.com/report-store/lipodystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Some of the Key Facts of the Lipodystrophy Market Report
• The estimated clinical prevalence of…
Dihydroorotate Dehydrogenase (DHODH) Inhibitors Market Expected to Witness Signi …
The Dihydroorotate Dehydrogenase (DHODH) Inhibitors market is expected to experience robust growth during the forecast period (2022-2036), supported by increasing clinical interest in DHODH-targeted therapies across multiple therapeutic areas, including autoimmune disorders, hematological malignancies, solid tumors, and viral infections. The growing pipeline of next-generation DHODH inhibitors, coupled with expanding research into their immunomodulatory and anti-proliferative mechanisms, is anticipated to transform the competitive landscape over the coming decade.
DelveInsight's "Dihydroorotate Dehydrogenase (DHODH)…
Non-tuberculous Mycobacterial (NTM) Infections Market Expected to Witness Signif …
The Non-tuberculous Mycobacterial (NTM) Infections market is anticipated to witness substantial growth across the seven major markets (7MM) during the forecast period (2022-2036), driven by increasing disease prevalence, improved diagnostic capabilities, greater clinical awareness, and the development of innovative therapies targeting difficult-to-treat NTM infections. With pipeline candidates such as Epetraborole and NUZYRA (omadacycline) advancing through clinical development, the treatment landscape is expected to evolve significantly over the coming decade.
DelveInsight's "Non-tuberculous…
More Releases for Simplex
Coiny Exchange Partners with Simplex
CoinyExchange, a leading provider of white label digital asset exchange platform has partnered with Simplex, a global leader in crypto payment processing. The partnership will allow Coiny Exchange clients to offer instant cryptocurrency purchases with debit and credit cards to users in over 150 countries.
Why this partnership is a game changer
For too long new crypto users have faced hurdles when trying to purchase digital assets from slow approval processes to…
Prominent Herpes Simplex Virus Treatment Market Trend for 2025: Innovations Driv …
What industry-specific factors are fueling the growth of the herpes simplex virus treatment market?
The herpes simplex virus treatment market is expected to grow exponentially due to the rising occurrence of sexually transmitted infections. Such infections, often called sexually transmitted diseases or STDs, are caused by distinctive bacteria, viruses, or other microbes. They are transmitted through various bodily fluids, such as blood, semen, or vaginal secretions, during sexual contact with an…
Herpes Simplex Virus Treatment Market Insights, Forecast to 2031
A new Report by DataM Intelligence, titled "Herpes Simplex Virus Treatment Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031,"" offers a comprehensive analysis of the industry, which comprises insights on the Herpes Simplex Virus Treatment market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
This report has a complete table of contents, figures, tables, and charts, as well as insightful analysis. The…
Simplex vs. Duplex: Comparing Optical Fiber Configurations for Today's Networks
In the evolving landscape of telecommunications, the choice between simplex and duplex optical fiber configurations is critical for network designers and operators. As businesses and consumers demand higher speeds and more reliable connections, understanding the unique advantages of each fiber type becomes essential.
Simplex optical fiber [https://www.sdgicable.com/products-detail/id-17.html], characterized by their single-threaded design, are predominantly used for one-way data transmission. They are ideal for applications where data only needs to travel in…
Comprehensive Access Control Solutions from Simplex for Enhanced Workplace Secur …
Simplex Time Recorders, a trusted leader in innovative time management and security solutions, is delighted to present its access control solutions portfolio. With a proven track record of delivering dependable and efficient time recording and management systems, Simplex is committed to revolutionizing workplace security and efficiency with its cutting-edge access control systems.
In today's rapidly evolving business landscape, managing and securing physical and logical access to workplaces is more crucial than…
Herpes Simplex Virus Treatment Market Insights, Forecast to 2031
Herpes Simplex Virus Treatment Market 2023 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Herpes Simplex Virus Treatment industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2023 to 2031 time period. It…
